Results 211 to 220 of about 15,380 (223)

Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?

Oncologist, 2014
Kathleen K Christians, Susan Tsai, Mhs, Tracy Kelly   +2 more
exaly  

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Lancet Oncology, The, 2017
Bonny B Morris, Heidi D Klepin, Umit Topaloglu   +2 more
exaly  

Metastatic pancreatic cancer—is FOLFIRINOX the new standard?

Nature Reviews Clinical Oncology, 2011
exaly  

[FOLFIRINOX, nab-paclitaxel + gemcitabine].

Nihon rinsho. Japanese journal of clinical medicine, 2015
openaire   +1 more source

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis

Cancers, 2019
Sara Pusceddu, Michele Ghidini, Francesca Corti   +2 more
exaly  

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer

Journal of Surgical Oncology, 2013
Brian A Boone, Amer H Zureikat, Nathan Bahary   +2 more
exaly  

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial

The Lancet Gastroenterology and Hepatology
Knut Jørgen Labori, Bobby Tingstedt, Asif Halimi   +2 more
exaly  

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Yearbook of Surgery, 2012
openaire   +1 more source

FOLFIRINOX cost effective for advanced pancreatic cancer

PharmacoEconomics & Outcomes News, 2017
openaire   +1 more source

Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial

Cancer Cell
Jun Yu
exaly